Latest Doxorubicin Stories
Enrollment in Phase 1 Study of MM-302 in HER2 Positive Breast Cancer Patients Initiated by Merrimack Pharmaceuticals Cambridge, MA (PRWEB) August 08, 2011 Merrimack Pharmaceuticals, Inc.
SAN FRANCISCO, July 18, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the European Medicines Agency Committee for Orphan Medicinal Products (COMP) has issued a positive opinion on its application for orphan medicinal product status for the company's lead oncology candidate, NKTR-102, for the treatment of women with ovarian cancer. "There is a significant unmet need for additional treatments to address ovarian cancer," said Carlo DiFonzo, PhD, Vice President of...
SEATTLE, June 17, 2011 /PRNewswire/ -- Cell Therapeutics, Inc.
SEATTLE, June 14, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) today announced that it met with the U.S. Food and Drug Administration's (the "FDA") Division of Oncology Drug Products (the "DODP").
CHICAGO, June 5, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from a subpopulation of patients in a Phase 2 clinical study evaluating single-agent NKTR-102 in women with platinum-resistant/refractory ovarian cancer.
SEATTLE, May 20, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTICD and MTA: CTIC) announced today that it will meet with the U.S.
SOUTH SAN FRANCISCO, Calif., May 19, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced updated results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma.
- An imitative word; an onomatopoetic word.